Clinical trial · Observational
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia
NCT07113132CI-TRIAL-00093385not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
aim of the work 1. To evaluate the presence of SF3B1-K700E mutation in acute lymphoblastic leukemia and chronic lymphocytic leukemia. 2. To determine the correlation between the presence of SF3B1-K700E mutation with other laboratory findings.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia ALL | Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
| Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- all patients group
- description
- peripheral blood samples of 28 acute lymphoblastic leukemia patients
- label
- cll patients
- description
- peripheral blood samples of 28 chronic lymphocytic leukemia patients
- label
- control group
- description
- peripheral blood samples of 28 control
Primary outcomes (2)
- measure
- 1- To evaluate the presence of SF3B1-K700E mutation in acute lymphoblastic leukemia and chronic lymphocytic leukemia using PCR technique
- timeFrame
- 2 years
- description
- ARMS PCR technique will be used to detect the presence of SF3B1-MUTATION in acute lymphoblastic leukemia and chronic lymphocytic leukemia
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with acute lymphocytic leukemia or chronic lymphocytic leukemia of both genders at any age. Exclusion Criteria: * Patients with any other type of malignancies
References
Publications (3)
- BACKGROUNDCilloni D, Itri F, Bonuomo V, Petiti J. SF3B1 Mutations in Hematological Malignancies. Cancers (Basel). 2022 Oct 8;14(19):4927. doi: 10.3390/cancers14194927. PMID 36230848
- BACKGROUNDWang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29;365(26):2497-506. doi: 10.1056/NEJMoa1109016. Epub 2011 Dec 12. PMID 22150006
- BACKGROUNDHan C, Khodadadi-Jamayran A, Lorch AH, Jin Q, Serafin V, Zhu P, Politanska Y, Sun L, Gutierrez-Diaz BT, Pryzhkova MV, Abdala-Valencia H, Bartom ET, Buldini B, Basso G, Velu SE, Sarma K, Mattamana BB, Cho BK, Obeng RC, Goo YA, Jordan PW, Tsirigos A, Zhou Y, Ntziachristos P. SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia. Sci Adv. 2022 Jan 21;8(3):eabj8357. doi: 10.1126/sciadv.abj8357. Epub 2022 Jan 21. PMID 35061527